The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
Subscribe To Our Newsletter & Stay Updated
